Clinical Trial

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine if the radiotracer, \[68Ga\]Ga-ABY-025, used for PET imaging can help us better identify and visualize lesions or tumors, in patients who are receiving standard of care therapy HER2+ cancers.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-09
Trial Details
NCT Number NCT06828588
Lead Sponsor Vanderbilt-Ingram Cancer Center
Conditions Locally Advanced Cancer, Metastatic Cancer, HER2, HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, HER 2 Low-expressing Breast Cancer
Enrollment 30 participants
Start Date 2026-04-16
Primary Completion 2027-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-08